Trials / Completed
CompletedNCT02859766
Safety and Pharmacokinetics of Abicipar Pegol Intravitreal Injections in Patients With Neovascular AMD
Evaluation of Safety and Systemic Pharmacokinetics After Single and Repeat Doses of Abicipar Pegol (AGN-150998) Intravitreal Injections in Patients With Neovascular Age-Related Macular Degeneration
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Allergan · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the safety and characterize the systemic pharmacokinetics (PK) of free and vascular endothelial growth factor (VEGF)-bound abicipar following single and multiple intravitreal injections of abicipar pegol in treatment-naïve patients with neovascular age-related macular degeneration (AMD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Abicipar pegol | Abicipar pegol 2 mg administered to the study eye by intravitreal injection. |
Timeline
- Start date
- 2016-12-07
- Primary completion
- 2017-10-20
- Completion
- 2017-10-20
- First posted
- 2016-08-09
- Last updated
- 2018-02-08
Locations
18 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02859766. Inclusion in this directory is not an endorsement.